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Abstract
Background: Many studies have found that smoking reduces lung function, but the relationship between cigarette
smoke and allergic asthma has not been clearly elucidated, particularly the role of mast cells. This study aimed to
investigate the effects of smoke exposure on allergic asthma and its association with mast cells.
Methods: BALB/c mice were sensitized and challenged by OVA to induce asthma, and bone marrow-derived mast
cells (BMMCs) were stimulated with antigen/antibody reaction. Mice or BMMCs were exposed to cigarette smoke
or CSE solution for 1 mo or 6 h, respectively. The recruitment of inflammatory cells into BAL fluid or lung tissues
was determined by Diff-Quik or H&E staining, collagen deposition by Sircol assay, penh values by a whole-body
plethysmography, co-localization of tryptase and Smad3 by immunohistochemistry, IgE and TGF-b level by ELISA,
expressions of Smads proteins, activities of signaling molecules, or TGF-b mRNA by immunoblotting and RT-PCR.
Results: Cigarette smoke enhanced OVA-specific IgE levels, penh values, recruitment of inflammatory cells
including mast cells, expressions of smad family, TGF-b mRNA and proteins, and cytokines, phosphorylations of
Smad2 and 3, and MAP kinases, co-localization of tryptase and Smad3, and collagen deposition more than those of
BAL cells and lung tissues of OVA-induced allergic mice. CSE solution pretreatment enhanced expressions of TGF-b,
Smad3, activities of MAP kinases, NF-B/AP-1 or PAI-1 more than those of activated-BMMCs.
Conclusions: The data suggest that smoke exposure enhances antigen-induced mast cell activation via TGF-b/
Smad signaling pathways in mouse allergic asthma, and that it exacerbates airway inflammation and remodeling.
Background
Cigarette smoke contains many toxic substances and a
strong pro-inflammatory stimulus [1-3]. It is widely
recognized as a significant risk factor for a number of
diseases including emphysema, chronic obstructive pul-
monary disease, cardiovascular disease, lung cancer and
allergic diseases [1].
Effects of smoke on allergic airway inflammation in
mice have reported both exacerbation [4-8] and attenua-
tion [9-11], although these studies could not be directly
compared due to differences in the various factors used,
such as mouse strain, the routes and manners of allergen
sensitization and smoke exposure. Smoke also enhanced
airway hyperresponsiveness [12], but not IgE levels and
eosinophils in mouse allergic model [12,13].
One particular factor which is involved in smoke-
induced airway remodeling is transforming growth factor
(TGF-b) [14]. The intracellular TGF-b-induced signaling
pathway is mediated through the Smad pathway in
inflammation in asthma [14-16]. TGF-b-producing T
cells can suppress airway inflammation and hyperrespon-
siveness induced by Th2 effector cells in a murine allergic
airway model [17,18]. However, it was recently shown
that TGF-b/Smad2 signaling proteins were expressed in
the majority of cells infiltrating into the airway in mouse
models [19-22] and human asthma [19,23].
Mast cells are well-known as major effector cells for IgE-
mediated allergic reactions such as asthma. Mast cells are
activated by cross-linking of antigen-specific IgE bound to
the high-affinity receptor (FcεRI) on their membranes.
Activated mast cells secrete preformed mediators (hista-
mine, tryptase, chymase, TNFa,a n do t h e rp r o t e i n s )a s
well as newly synthesized proinflammatory mediators such
as PGD2, leukotrienes, cytokines, and chemokines [24].
These mediators contribute to airway inflammation and
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any medium, provided the original work is properly cited.remodeling in allergic asthma [24,25]. TGF-b also acts as a
negative regulator of mast cell function, TGF-b/Smad3-
mediated signaling is essential for maximal cell growth in
mast cells [26] and mast cell development via p38 kinase
[ 2 7 ] .T h e r ea r ea l s oc o n t r o v e r sial reports that cigarette
smoke extract (CSE) solution contributes to the pathogen-
esis of emphysema and inflammation through proinflam-
matory chemokine production in mouse bone marrow-
derived mast cells (BMMCs) [28], and that it suppresses
allergic activation of in BMMCs [29].
Despite reports described above, cigarette smoke is con-
troversial in development of allergic asthma, and a role of
mast cells caused by smoke exposure has not been well
understood, although they are related to allergic asthma.
Therefore, we aimed to investigate whether cigarette
smoke influences allergic/asthmatic reaction in mice, and
whether mast cells are related to allergic reaction evoked
by smoke exposure. We observed that cigarette smoke
exposure exacerbates mouse airway inflammation and tis-
sue remodeling via TGF-b/Smad proteins expressed by
activated mast cells.
Methods
Reagents
Ovalbumin (OVA), alum (aluminum hydroxide, 2% Alhy-
drogel), methacholine, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), hematoxylin, eosin,
PAS, van Gieson solution, DNP-BSA, anti-DNP IgE anti-
body, SB431542 were obtained from Sigma-Aldrich (St.
Louis, MO); Cigarette (Marlboro) from Philip Morris
(Lausanne, Switzerland); aprotinin, leupeptin from Roche
(Baselm Switzerland); FITC-coupled goat anti-rabbit,
Texas Red-coupled goat anti-mouse, lipofectamine from
Invitrogen (Carlsbad, CA); Diff-Quick stain solution from
International Reagents Corp. (Tokyo, Japan); May Grün-
wald-Giemsa solution, PD98059, SP600126, SB203580,
PP2, piceaterol from Merck (Darmstadt, Germany); nitro-
cellulose membranes, chemiluminescent, [g
32P]ATP (spe-
cific activity, 3,000 Ci/mmol) from American Biosciences
(Buckinghamshire, UK); peroxidase-conjugated goat anti-
biotin antibody, mouse IgE from BD Biosciences (San
Diego, CA); Sircol assay kit from Biocolor Ltd. (Carrickfer-
gus, UK); primary-rabbit anti-Smad3, mouse anti-tryptase,
Smad2, Smad 3, ERK, JNK, p38, PAI-1 from Santa Cruz
Biotechnology (Santa Cruz, CA); HRP-conjugated rabbit
anti-goat IgG from Zymed Laboratory Inc. (San Francisco,
CA); TRIZOL from Molecular Research Center Inc. (Cin-
cineti, OH); amfiRivert one-step RT-PCR kit from GenDE-
P O T( B a r k e r ,T X ) ;a n t i - T G F - b,I L - 4 ,- 5 ,- 6 ,T N F - a,
biotinylated anti-TGF-b from BD Pharmingen (San Diego,
CA); anti-IL-13 from R&D system (Minneapolis, MN);
Silence Express Kit from Ambion Inc (Austin, TX); the
oligonucleotide of NF-B from Promega (Madison, WI);
filter from Millipore (Bedford, MA).
Sensitization and antigen challenge protocol
Specific pathogen-free fema l eB A L B / cm i c e( O r i e n t a l
Ltd, Seoul, Korea), 8 weeks of age, weighing approxi-
mately 20 g, were divided into four groups (8 mice/
group). PBS/NS, mice sensitized and nebulized by PBS
without smoke exposure; OVA/NS, mice sensitized and
nebulized by OVA without smoke exposure; PBS/S,
mice sensitized and nebulized by PBS with smoke expo-
sure; OVA/S, mice sensitized and nebulized by OVA
with smoke exposure. Hereafter, we used these group
abbreviations to clarify the text. Mice were sensitized
with 10 μg OVA (Grade V) adsorbed in 250 μg/200 μl
of alum (aluminum hydroxide, 2% Alhydrogel) by i.p.
injection on day 0, 5, 14, 21, and 28 (general sensitiza-
tion) in all mice except control sensitized with PBS.
One week after the final injection, mice were nebulized
with 2% OVA for 7 consecutive days from day 35 to 41
(local challenge) using nebulizer (Mega Medical, Seoul,
Korea), and then were again nebulized with 2% OVA on
day 49. All controls were nebulized by PBS with or
without smoke exposure at same times. All mice were
sacrificed the following day (Figure 1A). General sensiti-
zation and local challenge were performed 10 min after
final cigarette exposure.
Cigarette smoke exposure in mice
The cigarette smoke exposure system used was a modi-
fication of one described previously [4]. Briefly, mice
were subjected to whole-body mainstream cigarette
smoke exposure produced by a cigarette in a Plexiglas
chamber (16 × 25 × 16 cm) with an inlet for pressurized
air (air: smoke = 3:1), connected to a smoking machine
designed by Smoking Tester (Threeshine Com, Daejeon,
Korea). Mice were exposed from day 20 to day 49 (30
days, subacute exposure model) according to the injec-
tion schedule of experimental protocol: on the first day
(day 20), the smoke of a cigarette was administered for
10 min, and on the second day the smoke of two cigar-
ettes was administered. The amount of cigarette smoke
was gradually increased daily by one cigarette per day
for five days. The interval between smoke exposures was
15 min. After the fifth day, the animals were exposed to
five cigarettes/day from day 25 to day 49. We chose
Marlboro cigarette for smoke exposure because total
particulate matter (TPM, 56.7 ± 5.0 × 10
-3/ml acridine
orange units) of Marlboro cigarette is similar to TPM
values of Kentucky Reference 2R4F (63.1 ± 4.6 × 10
-3/
ml acridine orange units) [30].
All animals were housed in accordance with guidelines
from the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC), and all protocols
were approved by the Institutional Review Board and
conducted in the Laboratory Animal Research Center of
Sungkyunkwan University.
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Page 2 of 16Figure 1 Experimental protocol and effect of smoke exposure on the recruitment of inflammatory cells into BAL fluid or lung tissues
of OVA-induced asthmatic mice. BALB/c mice were sensitized with 10 μg OVA adsorbed in alum (250 μg) and nebulized with 2% OVA using
nebulizer and exposed to smoke for 30 days (days 20 days 49) as described in “Materials and Methods” (A). PBS/NS, mice sensitized and
nebulized by PBS without smoke exposure; OVA/NS, mice sensitized and nebulized by OVA without smoke exposure; PBS/S, mice sensitized and
nebulized by PBS with smoke exposure; OVA/S, mice sensitized and nebulized by OVA with smoke exposure. General sensitization and local
challenge were performed 10 min after final smoke exposure. BAL fluid collection was performed as described in “Materials and Methods”. After
Diff-Quik staining, differential cell counts were obtained by counting over 300 cells (B). Numbers of mast cells were determined in BAL cells
collected by Cytospin or in lung tissues sectioned (3 μm) in 200 × 200 μm area under microscopy using May Grünwald-Giemsa staining (C). Data
are shown as mean ± SEM for each group (n = 8). **, P < 0.01; ***, P < 0.001 versus PBS/NS mice.
†, P < 0.05;
††, P < 0.01;
†††, P < 0.001 versus
OVA/NS mice.
‡, P < 0.05;
‡‡, P < 0.01;
‡‡‡, P<0.001 versus PBS/S mice.
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Blood was collected by cardiac puncture and analyzed
for OVA-specific IgE by ELISA [31]. Briefly, microplates
coated with rat anti-mouse IgE were treated with mouse
sera followed by biotinylated OVA. Reactions were read
using an ELISA plate reader at 415 nm (see additional
file for details).
BAL fluid
BAL fluid was collected, stained and counted using meth-
ods previously described [31]. Numbers of infiltrated
inflammatory cells or mast cells stained with Diff-Quick
and May Grünwald-Giemsa [32], respectively, were quan-
tified under microscopy (see additional file for details).
Lung histology
After BAL had been performed, lungs tissue sections
embedded in paraffin (3 μm) were stained with hematox-
ylin and eosin (H & E) for general morphology, with peri-
odic acid-Schiff (PAS) for identification of goblet cells
[31], with van Gieson for collagen deposition [33] and
with May Grünwald-Giemsa for mast cells [32] (see addi-
tional file for details). Collagen amounts were assessed by
the Sircol collagen assay according to the manufacturer’s
instruction (see additional file for details) [34].
The mean linear intercept (Lm) was determined by
Lee et al. method [S1] (see additional file for details).
Measurement of airway hyperresponsiveness
Airway responsiveness was measured in mice 24 h after
the last challenge in conscious, spontaneously breathing
mice using a whole-body plethysmography system (All
Medicus Co., Seoul, Korea), as described previously [9,12].
Briefly, mice were placed in chamber and allowed to settle
for 5 ~ 10 min, and the chamber-pressure-time wave was
continuously measured via a transducer connected to a
computer data-acquisition system. After baseline Penh
reading for over a 5 min, mice were serially exposed to
increasing concentrations of nebulized MCh (0, 3.125,
6.25, 12.5, 25 and 50 mg/ml) (Sigma-Aldrich, St. Louis,
MO) in PBS for 2 min by inhalation. Penh values, which
are measured as changes in enhanced pause, tidal volume
(Vt), and breading frequency (breaths/minute) for the first
2 min after the end of MCh nebulization were averaged
and used to compare responses between smoke exposure
groups. Minute volumes were calculated by multiplying
the Vt and breathing frequency.
Immunohistochemistry (IHC)
Sections (μm) prepared in “Lung histology” were incu-
bated with primary rabbit anti-Smad3 or mouse anti-
tryptase, FITC-coupled goat anti-rabbit and Texas Red-
coupled goat anti-mouse, and examined under Confocal
microscopy (LSM 5 Exciter, Carl Zeiss, Oberkochen,
Germany) [35]. The degree of IHC color (yellow) devel-
oped by co-localization was quantified by intensity in
100 × 100 μm areas under microscopy (5 areas/each
slide × 8 mice/each group = 40 areas), and then mean ±
SEM for 40 areas was presented by histogram (see addi-
tional file for details). Right lungs were removed and
stored at -70°C for measurements of mRNA and protein
expression.
Preparation of the cigarette smoke extracts (CSE)
Water-soluble extract of cigarette smoke was prepared
using the following method. Briefly, mainstream smoke
from two commercial cigarettes was drawn through 7 ml
RPMI-1640 media by application of a vacuum. Optical den-
sity (O.D) of cigarette smoke extract (CSE) solution was
usually 2.0 ~ 2.4 at 340 nm when it was measured by spec-
trophotometer. This solution was filtered through a 0.22
μm pore size filter to remove bacteria and large particles.
The CSE solution was freshly prepared before each experi-
ment, and used within 10 min of preparation. In order to
confirm cell viability in CSE solution, an MTT assay was
performed (Additional file 1, Figure S1). The CSE solution
was used in the stimulation of BMMCs at final concentra-
tion of 0.1, 0.5, and 1.0% [36]. Optimal concentration and
time of CSE solution for BMMCs stimulation were 1.0%
and 6 h, respectively, in preliminary experiments.
Culture and activation of Bone marrow-derived mast cells
(BMMCs)
Bone marrow cells flushed from femurs and tibias of
BALB/c mice (female, 8 wk old) were cultured in RPMI-
1640 and 50% WEHI-3B conditioned media for 5 wk
and confirmed as described previously [32] (see addi-
tional file for details).
BMMCs (1 × 10
6 cells) were sensitized with anti-DNP
IgE antibody (0.1 μg/ml) overnight at 37°C. The cells were
washed and then challenged with 1.0 ng/ml DNP-HSA for
time periods indicated (optimal time, 6 h) at 37°C in Tyr-
ode’sb u f f e r[ 3 2 ] .C S Es o l u t i o nw a st r e a t e df o r6hi n
DNP-HSA stimulation. MAP kinase inhibitors (50 μM
PD98059 for ERK, 10 μM SP600125 for JNK, and 10 μM
SB203580 for p38 kinase) or TGF-b receptor kinase inhi-
bitor (10 μM SB431542) were added 30 min before DNP-
HSA stimulation. Lyn and Syk kinase inhibitors (10 μM
PP2 and 25 μM piceaterol, respectively) were added 10
min before DNP-HSA stimulation. In all experiments,
optimal time and concentration were first determined in
preliminary experiments.
Immunoblotting for proteins
Immnunoblotting was conducted using a method pre-
viously described [31]. Briefly, BAL cells (1 × 10
6 cells),
lung tissues (50 mg) or BMMCs (1 × 10
6 cells) were
homogenized in lysis buffer, and then each protein was
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details).
Smad3 siRNA transfection
Smad3 siRNA-expressing vectors were generated using
the Silencer Express Kit. Sense hairpin siRNA (ACA
CTA CAC AAA TGT TCC ACT GGG CTG AGA ACC
GGT GTT TCG TCC TTT CCA CAA G) and anti-
sense hairpin siRNA (CGG CGA AGC TTT TTC CAA
AAA ATT CTC AGC CCA GTG GAA CAC TAC ACA
AAT G) template oligonucleotide, specific to Smad3
mRNA, were used [37].
Transfection was carried out according to the manu-
facture’sm e t h o d .B r i e f l y ,1μgv e c t o rt h a te x p r e s s e s
Smad3 siRNA or control siRNA was incubated with 50
μl of serum free media for 5 min (Solution A), and 2 μl
lipofectamine 2000 incubated with serum free media for
5 min (Solution B). Solution A was mixed with solution
B, and incubated for 20 min. After incubation, BMMCs
were added to the mixer. Transfected-BMMCs were
activated with anti-DNP IgE antibody (0.1 μg/ml) and
DNP-HSA (1.0 ng/ml) as methods described previously
[32], and then the activities of MAP kinases, NF-B,
PAI-1 and expressions of cytokines were measured
using western blot and RT-PCR, respectively.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated from BAL cells (1 × 10
6
cells), lung tissues (50 mg) or BMMCs (1 × 10
6 cells)
using Trizol reagent. RT-PCR was performed in a final
volume of 50 μl using an amfiRivert one-step RT-PCR kit
in an automated thermal cycler (BIOER Technology,
Hangzhou, China). PCR assays were performed for 35
cycles. PCR products were analyzed using 1.0% agarose gel
containing ethidium bromide (EtBr) [31] (see additional
file for details).
ELISA
TGF-b, IL-4, IL-5, IL-13, TNF-a,a n dT G F - b (total and
active forms) levels in lung tissue homogenates (1 mg/500
μl PBS) or in supernatants of activated BMMCs (1 × 10
6
cells) were determined by ELISA (see additional file for
details).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from BMMCs (1 × 10
6
cells) and quantified using Bradford’sm e t h o d ,a n dt h e n
electromobility shift assay were performed using the
method previously described [31] (see additional file for
details).
Statistical analysis
Experimental data are presented as mean ± SEM.
ANOVA was used for statistical analysis. An analysis of
significance between each control group and experimen-
tal group was carried out with the SPSS statistic pro-
gram ver.12 (SPSS Inc., Chicago, IL). P values < 0.05
were regarded as significant. However, the symbols com-
paring to OVA/S mice and OVA/NS mice or PBS/S
mice was not indicated in some figures to avoid com-
plexity. The relationship between OVA/NS and OVA/S
mice was determined by linear regression analysis. The
r
2 w a su s e da sam e a s u r eo fh o ww e l lt h ed a t af i tt h e
regression line. The densitometry analysis of immuno-
blots, PCR and EMSA was performed with Quantity
One version 4.6.3 (BIO-RAD, Hercules, CA), and load-
ing control used for bad images was not shown in all
data. Histogram for densitometry analysis was indicated
by mean ± SEM (n = 4) obtained from four independent
experiments.
Results
Inflammatory cell recruitment into BAL fluid or lung
tissues
We observed that OVA/S mice (24.5 ± 3.90 × 10
4 cells)
enhanced recruitment of inflammatory cells (i.e., macro-
phages, neutrophils, and eosinophils, especially macro-
phage levels), compared to OVA/NS mice (17.2 ± 2.85 ×
10
4 cells). PBS/S mice (15.7 ± 1.80 × 10
4 cells) also
showed enhanced inflammatory cells versus the PBS/NS
mice (2.3 ± 0.51 × 10
4 cells) (Figure 1B). The total cells
(r
2 = 0.181, P = 0.014) and each inflammatory cells
(Additional file 1, Figure S2) in BAL fluid of OVA/S mice
were correlated with those of OVA/NS mice.
The numbers of mast cells were also elevated in OVA/
S mice (12 ± 1.1 cells) by 50% compared to OVA/NS
mice (8 ± 1.3 cells) in 200 × 200 μm areas under micro-
scopy. PBS/S mice had elevated numbers of mast cells
in BAL fluid, compared to PBS/NS mice (6 ± 1.1 cells
versus 0 ± 0.0 cells) (Figure 1C).
In lung tissues, the numbers of mast cells were ele-
vated in OVA/S mice (36 ± 1.2 cells) by 63.6%, com-
pared to OVA/NS mice (22 ± 1.0 cells) or PBS/S mice
(28 ± 1.2 cells) in 200 × 200 μm areas under microscopy
(PBS/NS mice, 0 ± 0.0 cells) (Figure 1C). The increased
mast cells in BAL fluid and lung tissues of OVA/S mice
were positively correlated with those of OVA/NS mice
(r
2 = 0.578, P = 0.029 for BAL cells; r
2 = 0.679, P =
0.044 for lung tissues) (Additional file 1, Figure S2).
Histopathologic changes in lung tissues
We further observed increases in inflammatory cell infil-
tration in peribronchial and perivascular areas, thicken-
ing of the airway epithelium in the OVA/S mice,
compared to OVA/NS mice (Figure 2A). And, mean lin-
ear intercept (Lm) for emphysema was enhanced in the
OVA/S mice (43.8 ± 1.22 μm ) ,c o m p a r e dt oO V A / N S
mice (35.2 ± 0.69 μm) or PBS/S mice (36.7 ± 0.48 μm).
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Page 5 of 16Figure 2 Effects of smoke exposure on histopathological changes, goblet cell hyperplasia or collagen deposition in lung tissues of
OVA-induced asthmatic mice. Experimental conditions and group symbols used were described in Figure 1. Lung tissues were fixed with 4%
paraformaldehyde, sectioned, and stained with hematoxilin and eosin (H & E) for general morphology (A) or periodic acid-Schiff (PAS) for goblet
cell hyperplasia (B), and van Gieson (pink color) for collagen deposition (C) (magnification: × 200) and collagen amounts (D, right panel).
Histogram indicates percentages in the numbers of PAS-positive goblet cells/total cells in 10 sites of 100 × 100 μm areas under microscopy (D,
left panel). Bars in control (PBS/NS) image indicate 50 μm. Arrows in OVA/NS of B panel indicate goblet cells (pink color). Collagen amounts
were assessed by the Sircol collagen assay. Data are shown as mean ± SEM for each group (n = 8). ***, P < 0.001 versus PBS/NS mice.
†, P <
0.05;
†††, P<0.001 versus OVA/NS mice.
‡, P < 0.05;
‡‡‡, P < 0.001 versus PBS/S mice.
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tional file 1, Figure S3). However, the LM value for
OVA/NS mice was weakly enhanced compared to PBS/
NS mice, but there were no statistical difference.
Airway tissue remodeling is characterized by the gob-
let cell hyperplasia, deposition of collagen and hypertro-
phy of airway smooth muscle. We found that OVA/S
mice (12.8 ± 0.74 cells/17.4 ± 0.63 total cells = 73.4%)
had enhanced goblet cell hyperplasia (Figure 2B, 2D left
panel) in the lumen of bronchi (10 sites of 100 × 100
μm areas under microscopy), compared to OVA/NS
mice (8.6 ± 0.43 cells/14.2 ± 0.56 total cells = 60.7%) or
PBS/S mice (6.5 ± 0.79 cells/15.2 ± 0.49 total cells =
42.8%). The increased goblet cells in lung tissues of
OVA/S mice were positively correlated with those of
OVA/NS mice (r
2 = 0.502, P = 0.022). And, OVA/S
mice enhanced levels of collagen deposition (Pink color
in Figure 2C). Collagen amounts were enhanced in
OVA/S mice (22.2 ± 1.13 μg/ml) compared to that of
OVA/NS mice (16.8 ± 0.72 μg/ml). And, in lung tissues
of PBS/S mice, collagen amounts were enhanced, com-
pared to that of PBS/NS mice (Figure 2D right panel).
OVA-specific serum IgE levels
I no r d e rt om o r ec o n f i r mt h ea l l e r g i ca s t h m ar e s p o n s e s
caused by smoke exposure, the effect of smoke on
serum anti-OVA IgE level was also examined. Serum
OVA-specific IgE levels were elevated in OVA/S mice
(277.2 ± 7.58 ng/ml) more than that in OVA/NS mice
(228.1 ± 5.34 ng/ml), through both had levels higher
than in PBS/NS mice (0.5 ± 1.34 ng/ml) or PBS/S mice
(0.6 ± 1.67 ng/ml) (Table 1).
Airway hyperresponsiveness (AHR) to methacholine (MCh)
AHR was measured 24 h after final exposure. Baseline
Penh values were not significantly affected by allergic
challenge or smoking groups (from 0.51 ± 0.21 to 0.88 ±
0.39). Penh values OVA/NS mice had a significant
increase in MCh dose-dependent manner (from 3.125 to
50 mg/ml). OVA/S mice enhanced Penh values more
than those in OVA/NS or PBS/S mice (Figure 3A). PBS/S
mice also enhanced Penh values more than that in PBS/
NS mice, but did not show significant differences com-
pared to in OVA/NS mice. PC300 values were decreased
in OVA/NS mice (18.3 ± 1.15 mg/ml) compared to PBS/
NS mice (52.8 ± 4.06 mg/ml), and they were decreased in
OVA/S mice (4.3 ± 2.80 mg/ml) more than that in OVA/
NS or PBS/S mice (9.1 ± 1.17 mg/ml) (Figure 3B). Smok-
ing had effect on AHR in OVA-challenged mice.
Tidal volume (Vt) was weakly decreased with the
functional residual volume increase after mouse airways
were challenged with MCh. The Vt in OVA/NS mice
was inversely reduced with the increasing dosage of
MCh, and it was reduced in OVA/S mice more than
that in OVA/NS mice which were decreased compared
with PBS/NS mice (Additional file 1, Figure S3B).
Breathing frequency was increased in OVA/S mice more
than that in OVA/NS or PBS/S mice (Additional file 1,
Figure S3C). Minute volume was weakly decreased in
O V A / Sm i c ec o m p a r e dt oO V A / N So rP B S / Sm i c e
(data not shown).
Figure 3 The effects of smoke exposure on airway
hyperresponsiveness in OVA-induced asthmatic mice.
Experimental conditions and group symbols used were described in
Figure 1. Airway hyperresponsiveness was measured at 24 h after
last challenge using a whole-body plethysmography as described in
“Materials and Methods”. Airway responsiveness to aerosolized
methacholine (MCh) was measured in conscious, spontaneously
breathing mice. Mice were placed into the main chamber and were
nebulized first with PBS, then with increasing doses (1.56 to 50 mg/
ml) of MCh for 2 min for each nebulization. Readings of breathing
parameters were taken for 2 min after each nebulization during
which Penh values were determined (A). The PC300 represents the
dose of MCh which induces 300% increase in Penh (B). Data are
expressed as mean ± S.E.M. (n = 8). *, P < 0.05; **, p < 0.01; ***, p <
0.001 versus PBS/NS mice.
†, P < 0.05;
†††, P<0.001 versus OVA/NS
mice.
‡, P < 0.05;
‡‡, P < 0.01;
‡‡‡, P < 0.001 versus PBS/S mice.
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proteins in BMMCs
Enhancement of inflammatory cells (macrophages, neu-
trophils and eosinophils) was previously reported in
OVA-induced allergic mice exposed with smoke by other
[5,8,9] and our laboratories (Figure 1B and Figure 2A),
but enhancement of mast cells was not reported yet.
And, mast cells are involved in allergic inflammation and
remodeling [25] and cigarette smoking is linked to the
TGF-b/Smad signaling pathways in airway remodeling
[14]. Therefore, we focused on mast cells, and we first
examined the expressions of TGF-b/Smad proteins using
primary cells (BMMCs) in vitro. In BMMCs activated
with anti-DNP IgE/DNP-HSA reaction (refer to the acti-
vated-BMMCs), we observed higher mRNA expression of
Smads throughout a time course (left panel) and activity
(right panel) of Smads in the activated-BMMCs treated
with CSE (refer to CSE-treated/activated-BMMCs), com-
pared to the activated BMMCs (Addition file 1, Figure
S4A). And, mRNA levels (left column) and protein
expression (right column) of TGF-b were observed to
reach a maximum at each 3 h, and mRNA expression
and activity of Smad3 reached a maximum at each 6 h
(Figure 4A).
In order to investigate the mechanism of action of
s m o k ee x p o s u r eo nt o t a la n da c t i v eT G F - b release and
expression of all Smad proteins in BMMCs, we observed
that CSE- treated/activated-BMMCs) released total and
active TGF-b more than did only activated-BMMCs or
only CSE-treated cells (Table 2 right column).
Furthermore, protein or mRNA expression and phos-
phorylation of Smad3 was inhibited by TGF-b receptor
kinase inhibitor SB431542 (Addition file 1, Figure S4C),
but not by Lyn or Syk kinase inhibitor, PP2 and pice
(Addition file 1, Figure S4B).
Activities of MAP kinases or transcription factors in
BMMCs
MAP kinases phosphorylate Smad3 linker regions
through TGF-b-induced activation in various cells
[38,39]. In Figure 4B, the activities of MAP kinases were
enhanced in CSE-treated/activated-BMMCs, compared
to those of the activated-BMMCs (Figure 4B left panel).
MAP kinase inhibitors blocked phosphorylation of
Smad3 (Figure 4C) as well as phosphorylation of their
respective MAP kinases (data not shown).
We observed the enhanced NF-Ba n dA P - 1D N A
binding activity or expression of PAI-1 in nuclear
extracts from CSE-treated/activated-BMMCs, compared
to the activated-BMMCs. The enhancement in NF-B
and AP-1 or PAI-1 activity was reduced by inhibitors of
MAP kinases (Addition file 1, Figure S5A,B). Expression
patterns for transcription factors in lung tissues of
OVA/S mice also showed similar results to those of
BMMCs (data not shown).
Effects of Smad3 siRNA on the activities of MAP kinases,
transcription factors and cytokine expression in BMMCs
TGF-b signaling pathways include the TGF-b type I recep-
tor (TbRI)/C-terminal phosphorylated Smad3 (pSmad3)
pathway. Therefore, we examined whether Smad3 siRNA
influenced the activities of MAP kinases and NF-B/PAI-1
downstream of Smad3 in activated-BMMCs. We per-
formed Samd3 siRNA in BMMCs’ cells, and Smad3
siRNA did not enhance the activities of pSmad3 (Figure
5A) and NF-B/PAI-1 in CSE-treated/activated-BMMCs
(Figure 5B), but the activities of MAP kinases were
enhanced regardless Smad3 siRNA (Figure 5C).
mRNA and protein expressions of cytokine in BAL cells
and lung tissues or BMMCs
Just as transcription factors NF-B and AP-1 regulate the
production of various inflammatory cytokines, we
observed that mRNA of various cytokines (IL-1b,- 4 ,- 5 ,
-6 -10, -13, TNF a and IFNg) were enhanced in BAL
cells and lung tissues of OVA/S mice or CSE- treated/
activated-BMMCs versus those of OVA/NS mice or acti-
vated-BMMCs (Addition file 1, Figure S6). Each MAP
kinase inhibitor significantly attenuated the increase in
expression of cytokine mRNA (data not shown).
We also examined protein expression of some cyto-
kines (IL-4, -5, -6, -13, TNFa) among various inflamma-
tory cytokine mRNA (Addition file 1, Figure S6). These
cytokine expressions were enhanced in lung tissues of
OVA/S mice, compared to OVA/NS mice (Table 3).
And, Smad3 siRNA transfection did not enhance expres-
sion of cytokine mRNA in CSE treated/activated-
BMMCs (Figure 5D).
Expression of TGF-b and Smad family members in BAL
cells or lung tissues
Next, we further examined whether these phenomena
evoked by BMMCs in vitro were caused in OVA-
induced mice in vivo. We observed that expression of
TGF-b mRNA (Figure 6A) was higher in BAL cells or
lung tissues of OVA/S mice, compared to the levels in
OVA/NS mice or PBS/S mice. Amounts of total and
active TGF-b also were higher in lung tissues of OVA/S
mice than those of OVA/NS mice or PBS/S mice (Table
2 left panel).
We next observed that mRNA expression of Smad
family (Figure 6B) and phosphorylation of Smad2 and 3
(Figure 6C) induced by TGF-b signaling were more ele-
vated in BAL cells or lung tissues of OVA/S mice, com-
pared with those of OVA/NS mice. However, expression
of inhibitory Smad6 and 7 mRNA was decreased in BAL
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Page 8 of 16Figure 4 Effects of smoke exposure or MAP kinase inhibitors on the TGF-b expression, or Smad3 activity in BMMCs activated with
antigen/antibody reaction or in BAL cells and lung tissues of OVA-induced asthmatic mice. BMMCs (1 × 10
6 cells) were sensitized and
stimulated with 0.1 μg/ml anti-DNP IgE antibody and DNP-HSA (1.0 μg/ml) for 6 h, CSE solution (OD 2.0, 1.0%) was treated during DNP-HSA
stimulation. mRNA expressions and activities were determined using RT-PCR and western blot as described in “Materials and Methods”.
Experimental conditions for BAL cells and lung tissues and group symbols used are described in Fig. 1. MAP kinase inhibitors (50 μM PD98059
for ERK, 10 μM SP600125 for JNK, and 10 μM SB203580 for p38 kinase) were added 30 min before DNP-HAS stimulation. Mean ± SEM (n = 4) for
values measured by densitometry analysis was indicated by histogram. (A) Band images and histogram for time course in mRNA expression (left
panel) and activity (right panel) of TGF-b and Smad3. (B) Histogram for activities of MAP kinases. (C) Band images and histogram for activities of
Smad3 after pretreatment of MAP kinase inhibitors. Ag/Ab Rx, anti-DNP IgE antibody/DNP-HSA reaction; BM, BMMCs; -, +, without and with
substances. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control (BMMCs alone) or PBS/NS mice.
+, P < 0.05;
++, P < 0.01;
+++, P < 0.001 versus
BMMCs without MAP kinase inhibitor. In Figure 4A and 4B, the symbols comparing to OVA/S mice and OVA/NS mice or PBS/S mice was not
indicated to avoid complexity.
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Page 9 of 16Figure 5 Effects of Smad3 siRNA on activities of MAP kinases, NF-B/PAI-1, and expression of cytokines in BMMCs activated with
antigen/antibody reaction. Smad3 siRNA-expressing vectors were generated in BMMCs using the Silencer Express Kit. Transfected BMMCs (1 ×
10
6 cells) were activated with 0.1 μg/ml anti-DNP IgE antibody and DNP-HSA (1.0 μg/ml) for 6 h. CSE solution (OD 2.0, 1.0%) was treated during
DNP-HAS stimulation, as described in “Materials and Methods”. Expression or activity of Smad3, MAP kinases, transcription factors and cytokines
were determined in extract protein and nuclear protein extracts prepared from BMMCs using western blot and RT-PCR, respectively. Mean ± SEM
(n = 4) for values measured by densitometry analysis was indicated by histogram. (A) Band images and histogram for protein and activity of
Smad3. (B) Band images and histogram for expressions of NF-B and PAI-1. (C) Band images and histogram for activities of MAP kinases. (D)
Band images and histogram for cytokine mRNA expressions. BM, BMMCs; Ag/Ab Rx, anti-DNP IgE antibody/DNP-HSA reaction; -, +, without and
with Smad3 siRNA. ***, P < 0.001versus control (BMMCs alone).
+++, P < 0.001 versus CSE-treated/activated-BMMCs.
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Page 10 of 16Figure 6 Effects of smoke exposure on mRNA expressions of TGF-b and Smad family members in BAL cells or lung tissues of OVA-
induced asthmatic mice. Experimental conditions and group symbols used were described in Fig. 1. BAL cells or lung tissues were collected.
mRNA expressions of TGFb and Smads or Smad3 phosphorylation were analyzed by RT-PCR and western blot, respectively. Mean ± SEM (n = 4)
for values measured by densitometry analysis was indicated by histogram. (A) Band images (left panel) and histogram (right panel) for TGF-b
mRNA expressions. (B) Histogram for mRNA expressions of Smads. (C) Histogram for expressions and activities of Smad2/3. ***, P < 0.001versus
PBS/NS mice.
+++, P < 0.001 versus OVA/NS or PBS/S mice. In Figure 5B and 5C, the symbols comparing to OVA/S mice and OVA/NS or PBS/S
mice did not indicate to avoid complexity. The symbols comparing to OVA/S mice and OVA/NS mice or PBS/S mice was not indicated to avoid
complexity.
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Page 11 of 16cells and lung tissues of OVA/S mice, compared to
those of OVA/NS mice (Figure 6B).
As shown in activated-BMMCs (Figure 4B left panel),
the activities of MAP kinases were also enhanced in
BAL cells (middle panel) and lung tissues (right panel)
of OVA/S mice, compared to those of OVA/NS mice or
PBS/N mice (Figure 4B).
Co-localization of mast cell tryptase and Smad3 protein in
lung tissues
In order to investigate whether smoke-induced expres-
sion of Smad proteins was occurring in mast cells, we
examined co-localization of tryptase contained in mast
cell granules and Smad3 protein in lung tissues using
double staining. As shown in Figure 7A, lung tissues in
OVA/S mice enhanced the co-localization (yellow
color) of tryptase and Smad3 protein, compared with
PBS/S or OVA/NS mice. The intensity of co-localized
cells in 100 × 100 μm areas under microscopy (5
areas/each slide × 8 mice/each group = 40 areas) was
presented as histogram (Figure 7B).
Discussion
It has been reported that cigarette smoke may promote
[4-8] or actually suppress [9-11] allergic inflammation.
However, the mechanisms involved have not been eluci-
dated clearly. We observed that cigarette smoke exacer-
bates the development of allergic asthma by mast cell
activation through TGF-b/Smad signaling.
Cigarette smoke elevates the numbers of prominent
inflammatory cells such as macrophages and neutrophils
or goblet cells, and it enhances release of inflammatory
cytokines [3,4,40]. As smoke has adjuvant property
[5,7,8], these cells play important roles in the exacerba-
tion of asthmatic airway inflammation [4,5]. And, IL-4
plays an important role in B cell growth, differentiation,
and secretion of IgE and IL-13 [40,41]. Our data show-
ing that cigarette smoke augmented numbers of their
inflammatory cells, the mRNA and protein levels of IL-4
and IL-13 in BAL cells and lung tissues, or in BMMCs
and OVA-specific IgE levels and Penh values, are in
agreement with the previous reports that smoking
enhanced inflammatory cells, OVA-specific IgE produc-
tion, and cytokines.
Mast cells have been implicated in airway inflamma-
tion and remodeling [24,26], but long-term smoking
(4 mo) did not show enhanced numbers of mast cells in
OVA-induced lung tissues in vivo [13]. In contrast to
these findings, we observed that smoke elevated the
numbers of mast cells in BAL cells and lung tissues of
OVA/S mice, although both studies differed in various
factors such as smoke exposed periods and allergen
challenge.
Mast cells in tongue and esophageal submucosa
express TGF-b [42]. TGF-b attenuates release of media-
tors and de novo kit receptor expression through Smad
pathway in human skin mast cells [43]. However, TGF-
b is increased at the sites of allergic inflammation [23],
may contribute to tissue fibrosis and airway remodeling
[25,44], and is involved in smoke-induced airway remo-
deling [14]. TGF-b overexpression is associated with
initial events occurring during the emphysematous pro-
cess [45]. Furthermore, production of chemokines
increased in BMMCs activation by smoke exposure con-
tributes to the pathogenesis of emphysema and a local
inflammation [28]. Our data demonstrated that OVA/S
mice enhance emphysema and expressions of TGF-b
and Smad proteins in vivo and co-localization of mast
cells and Smad3 protein in lung tissues. We also infer
that OVA/NS mice may induce emphysema due to the
expression of TGF-b and Smad proteins in vivo,
although a degree of emphysema development is weaker
than that of OVA/S mice. This is the first report of
TGF-b/Smad pathways being involved in smoke-
exposed/OVA-induced activation of mast cells.
From our data, we can infer that the smoke-activated
mast cells produce TGF-b, which stimulates cell activa-
tion in an autocrine manner, or TGF-b released from
other cells activated by cigarette smoke may activate
mast cells (Figure 8). This inference was confirmed by
inhibitors of Lyn and Syk kinases, which are down-
stream kinases in FcεRI signaling pathways, and by
TGF-b receptor kinase inhibitor. This inference was also
supported by our observation that expression of Smad
proteins (a maximum expression at 6 h) occurred later
than TGF-b expression in BMMCs activation (a maxi-
mum expression at 3 h). However, in vivo, TGF-b is
produced not only by mast cells, but also by many other
cell types including T cells [18] and eosinophils [23].
This issue will require further study to better under-
stand the contributions of these other TGF-b-producing
cells.
In general, TGF-b activates TGF-b type I receptor
(TbRI) leading to direct phosphorylation of Smad3,
which transduces the TGF-b signal from the cell surface
to the nucleus, altering gene expression [46]. TGF-b sig-
naling pathways include the TbRI/C-terminal phos-
phorylated Smad3 (pSmad3C) pathway and the MAP
kinase-dependent linker phosphorylated Smad3
(pSmad3L) pathway. The pSmad3C is involved in cell
growth inhibition, and pSmad3L regulates invasive capa-
city and extracellular matrix deposition [38,39]. As
Smad3 activity was completely inhibited by MAP kinase
inhibitors, and activities of MAP kinases were increased
in CSE-treated/activated-BMMCs regardless Smad3
siRNA transfection, our finding is consistent with
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Page 12 of 16Figure 7 Effects of smoke exposure on co-localization of mast cell tryptase and Smad3 in lung tissues of OVA-induced asthmatic
mice. Experimental conditions and group symbols used were described in Fig. 1. Lung tissues were fixed with 4% paraformaldehyde, sectioned
and immunostained as described in “Materials and Methods”. Co-localization was examined by immunohistochemistry (A). The degree of IHC
color (yellow) developed by co-localization was quantified by intensity in 100 × 100 μm areas under microscopy (5 areas/each slide × 8 mice/
each group = 40 areas), and then mean ± SEM for 40 areas was presented by histogram (B). ***, P<0.001 versus PBS/NS mice.
†††, P < 0.001
versus OVA/NS mice.
‡‡‡, P < 0.001 versus PBS/S mice. Bar in control (PBS/NS) image indicates 50 μm.
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Page 13 of 16previous reports that MAP kinases exist to upstream of
Smad3 in other cells (pSmad3L pathway) [38,39].
Cigarette smoke induces NF-B and AP-1 in a variety
of cells [2,3,47], and it up-regulates the expressions of
inflammatory cytokines [3,4,41] and extracellular mole-
cules [48]. Moreover, cytokine genes are regulated by
NF-B and AP-1. Therefore, our data can be inferred
that smoke-activated mast cells produce TGF-b,a n d
mast cells activated with TGF-b enhance expressions of
cytokines via pSamd3L/NF-Ba n dA P - 1i nt h eO V A -
induced allergic responses (Figure 8).
Our finding for PAI-1 expression induced by smoke
exposure also supports previous reports that a complex
of pSmad3L associated with Smad4 undergoes transloca-
tion into the nucleus, where it binds to the Smad-bind-
ing element of the PAI-1 promoter, and induces its
transcriptional activity, leading to ECM deposition [49].
The induction of PAI-1 expression is related to collagen
deposition in murine asthma model [50]. In view of the
fact that Smad3 siRNA transfection did not induce the
activities of NF-B or PAI-1 in Smad3 downstream sig-
nal cascades in BMMCs, we suggest that cigarette
smoke may induce collagen deposition by mast cell acti-
vation through TGF-b/Smad signaling pathways.
Exposure to cigarette smoke alone (PBS/S mice) also
showed similar results seen in OVA/NS mice. Therefore,
it can be inferred that cigarette smoke exposure alone
may induce airway inflammation and tissue remodeling.
Carbon monoxide (CO)-containing smoke is related to
allergic responses to OVA [4,9] whereas other study
shows no relation [11]. Melgert et al. [9] reported that
smoke-exposed OVA mice, which have high levels of
carcoxyhemoglobin (COHb) in serum (22.5 ± 1.7%) as
compared to human smokers (4 ~ 10% COHb levels),
reduced airway inflammatory cells in BAL fluid, com-
pared to OVA mice (air instead of smoke). In our data,
COHb levels (23.2 ± 1.61%) in the serum of smoking
mice were similar to that of Melgert et al. [9]. However,
our data showed enhancement of allergic airway
responses in OVA/S mice. Therefore, we think that CO
was not a significant contributor to allergic responses.
However, it needs further study to better understand
the relation of CO in allergic responses.
It is difficult to compare the data stimulated in vivo
by whole body main stream cigarette smoke with the
data from BMMCs in vitro stimulated by CSE solution.
And, TGF-b production and activations of Smad3/
MAP kinases are induced by more cells than by just
mast cells. Therefore, our data do not support that
only mast cells play an important role in smoke-
exposed allergic asthma. However, as mast cells nor-
mally reside close to epithelium and blood vessels in
the airway, near smooth muscle and mucus-producing
gland, mast cells will be exposed and activated by anti-
gen and smoke faster than other cells. And, we
demonstrated numbers of mast cells enhanced in BAL
fluid and lung tissues, correlation of the increased
mast cells to smoke exposure, co-localization of mast
cell tryptase and Smad3 in lung tissues, and inhibition
of activities of signal molecules in BMMCs by Smad3
siRNA transfection. Therefore, we suggest that mast
cells may be one of important effector cells in mouse
allergic asthma exacerbated with smoke exposure, but
it needs further study. Extrapolation of our data to
human beings needs more study on further mechanism
in animal model.
Conclusions
T h ep r e s e n ts t u d ys u g g e s t st h a tc i g a r e t t es m o k ee x p o -
sure in part up-regulates antigen-induced mast cell acti-
vation associated with allergic asthma through TGF-b/
pSmadL/NF-B and AP-1 signaling pathway, and up-
regulated mast cells induce the production of cytokines
and collagen deposition, and then that it may exacerbate
airway inflammation and tissue remodeling in mouse
allergic asthma.
Figure 8 A schematic diagram of signaling pathway in mast
cells activated by antigen/antibody reaction and smoke
exposure in vivo and in vitro. The data suggest that smoke
exposure induces TGF-b release from a variety of cells including
mast cells. The released TGF-b activates mast cells through
expression of Smad isoforms such as TbRI/pSmad3C and pSamd3L
and subsequent activation of these proteins via MAP kinases. In this
way, it exacerbates allergic asthma symptoms. Question mark (?)
indicates TGF-b predicted to be produced by various cell types or
indicates predicted signaling cascade. The dotted arrow indicates a
response that was not determined in this study.
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Additional file 1: Figure S1: Cell viability of BMMCs by MTT assay
after stimulation with CSE. Optimal concentration and time of CSE
solution used for BMMCs stimulation were 1.0% and 6 h, respectively.
Figure S2: Correlations between inflammatory cells, mast cells and goblet
cells in OVA/NS and OVA/S exposed mice. Linear regression analysis for
relationship between OVA/NS and OVA/S mice showed a significant
relation with each r
2. The best fit lines represent the 95% of confidence
of data. Figure S3: Effects of smoke exposure on the mean linear
intercept (Lm), and tidal volume and breathing frequency in lung tissues
of OVA-challenged asthmatic mice. Lm values, which are shown as the
sum of the length of all counting lines divided by the total number of
counted intercepts, and respiratory functions including tidal volume and
breathing frequency measured at 48 h after last challenge were affected
by smoke exposure. Figure S4: Effects of smoke exposure, Lyn and Syk
kinase inhibitors, or TGF-b receptor kinase inhibitor on the expressions
and activity of Smads in BMMCs activated with antigen/antibody
reaction. Protein or mRNA expressions and phosphorylation of Smads
enhanced by CSE-treated/activated-BMMCs were inhibited by TGF-b
receptor kinase inhibitor (SB431542), but not inhibited by Lyn (PP2) or
Syk (piceatenol) inhibitor. Figure S5: Effect of smoke exposure or MAP
kinase inhibitors on activity of NF-B, AP-1 or PAI-1 in BMMCs activated
with antigen/antibody reaction. The enhancement of NF-B and AP-1 or
PAI-1 activity caused by CSE-treated/activated-BMMCs was reduced by
inhibitors of MAP kinases. Figure S6: Effect of smoke exposure on
expressions of cytokines in BAL cells and lung tissues of OVA-induced
asthmatic mice or in BMMCs activated with Ag/Ab reaction. Expression
of various cytokines was enhanced in BAL cells and lung tissues or CSE-
treated/activated-BMMCs more than that of OVA/NS or activated-BMMCs.
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